CD274 and lung carcinoma: Low-level background activity is especially important to correctly assess low-levels of expression, as it is the case for PD-L1, with for example cut-offs of only 1 to 5% positive cells in immunohistochemistry for optimal treatment selection in lung carcinoma patients [33].